Parimoo et al. (1) recently reported the occurrence of severe neuropathy after treatment with vinorelbine and paclitaxel (Taxol). This effect occurred in five patients with mild pre-existing sensory neuropathy due to previous exposure to neurotoxins. They also quoted the occurrence of neurologic damage with this combination in another unpublished trial (1). We have also been interested in this unique combination of cytotoxic agents based on significant in vivo preclinical synergy (2) and our own positive in vitro data using MCF-7 wildtype cells and median effect analysis. As previously reported, we found synergism when vinorelbine preceded paclitaxel and antagonism with the inverse schedule (3). Our experience in a phase I trial of female patients with breast cancer does not support the occurrence of severe neurotoxicity (4), as shown in Table 1 . Of note, unlike the reported trial from the Norris Comprehensive Cancer Center (1), only two of our patients received a neurotoxic agent prior to entry in the vinorelbine-paclitaxel study. In both cases, the drug was used in adjuvant treatment and several years had elapsed before relapse. Our patient exclusion was based on previous known concerns of findings of worsening preexisting underlying neurotoxicity with vinca alkaloid treatment (5,6). On the basis of emerging data with high-dose vinorelbine (7), we stopped dose escalation of this agent at 39 mg/m 2 per course. In addition, our vinorelbine treatment is divided over 3 days and repeated every month, giving a maximal theoretic dose intensity of 9.75 mg/m 2 per week and lower peak plasma concentration levels. Paclitaxel is given once monthly on a 3-hour schedule on day 3 (4). Parimoo et al.
(1) report a dose intensity of vinorelbine from 10 to 12.5 mg/m 2 per week and paclitaxel given every 2 weeks. The differing schedules of the above two studies may partially explain the differences. With the proper patient selection, the combination of vinorelbine with paclitaxel may have a substantial role in the future management of human malignant disease because of potential synergy and broad spectrum of antitumor effects. Although patients must be selected appropriately to exclude prior neurologic damage, we believe that this combination should not be excluded from further clinical investigation. Services; and by a grant from the Glaxo-Wellcome Company.
Response
Our letter on the severe neurotoxicity of vinorelbine-paclitaxel combinations was designed to alert clinicians to the potential for neurotoxicity and not to discourage further clinical studies. In fact, three of our patients showed some improvement in disease manifestations and lowering of tumor markers, suggesting antitumor activity worth pursuing. The experience described by Budman et al. indicates that one to five cycles (median, two cycles) may be given to 20 patients (not previously exposed to neurotoxic regimens) without resulting in more than grade 1 paresthesias. They appropriately point out the lower dose intensity of vinorelbine in their regimen and their different schedule (daily × 3 every 4 weeks versus the every-2-week schedule we employed). Just as relevant may be the dose intensity of paclitaxel that in their protocol varied from 135 to 200 mg/m 2 every 4 weeks, with most of their patients receiving 135 mg/m 2 . This represents a much reduced dose intensity from our 150 mg/m 2 every-2-week paclitaxel dose. The information provided by Budman and colleagues is helpful in planning additional studies with this combination. Our intention is to explore the less neurotoxic 24-hour schedule of paclitaxel together with vinorelbine to be repeated every 3 weeks in a phase I dose escalation study. The division of stage III disease in the current ISS was based on the principle that IIIA (T3 or N2) could theoretically benefit from complete surgical resection in contrast with IIIB (T4 and/or N3) (2). A surgical approach to this subset of patients leads to several critical observations. 1) N2 disease is an heterogeneous subcategory: patients with minimal N2 involvement that can be resected completely could achieve a 5-year survival rate of more than 30%, close to T3 N1 disease, while patients with patent histologically proven preoperative (clinical) N2 disease are associated with 5-year survival rates of less than 10%, quite similar to IIIB disease, according to the ISS (3).
2) Potentially resectable T4 N0 disease could be associated with 5-year survival comparable with clinical N2 disease (3,4).
3) IIIB (ISS) unresectable tumors may become resectable after induction treatments. The updated data of our pilot study, whose preliminary results were previously presented, confirm that complete surgical resection of stage IIIB (nonresectable) cancers could be achieved in more than 50% of the cases after induction treatment and is associated with a 2-year survival rate of 36% (5).
Several lung cancer workshops recently pointed out some pretreatment staging difficulties. As far as the T is concerned, the resectability of lung tumors associated with the invasion of the left pulmonary artery, thoracic aorta, vertebral bodies, or esophageal wall remains hard to ascertain. In addition, technically resectable invasion of the superior vena cava or of the main carina by the nodal disease is difficult to classify.
In attempting to establish some guidelines allowing the selection of homogeneous prognostic subgroups for clinical studies, we propose the following modifications: 1) the subdivision of N2 disease into two subcategoriesmN2 (clinical N2), clinically considered N0-N1 but pN2 postoperatively and cN2 (clinical N2), histologically proven at the first pretreatment staging; 2) the subdivision of T4 disease into two subcategories-T4 1 , including invasion of superior vena cava, left atrium, carina, trachea, great arteries (considered as potentially resectable in selected cases), and T4 2 , including invasion of the heart (except left atrium), esophagus, vertebrae, malignant pleural or pericardial effusion (considered as definitively unresectable; and 3) the subdivision of stage III into three subcategories-IIIA, including T3 N1, T1-T3 mN2; IIIB, including T1-T3 cN2, T4 1 N0-N2; and IIIC, including T4 2 , any N, any T N3.
In this way, the new staging system could set up obvious landmarks between the patients who have to receive primary surgical resection (stages I, II, and IIIA), the patients who could possibly benefit from induction therapy (stage IIIB), and the patients who are definitively excluded from surgical treatment (stages IIIC and IV) ( Table 1) . T1 N0  T1 N1  T3 N0  T3 N1  T4 1 N0-N2  T4 2 Any N  Any T Any N M1  T2 N0  T2 N1  T1-T3 mN2  T1-T3 cN2  Any T N3 *Primary surgery. †Induction. ‡No surgery.
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